FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s

The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy.